Adams Respiratory Therapeutics Inc

Adams Respiratory Therapeutics — Merger or Acquisition (May 2006)

11 slides from Adams Respiratory Therapeutics's merger presentation, May 25, 2006

  1. Slide 1: Adams Conference Call to Discuss Acquisition of Delsym 12-Hour Cough Suppressant Liquids From UCB

    Slide 1: Adams Conference Call to Discuss Acquisition of Delsym 12-Hour Cough Suppressant Liquids From UCB

    Adams Conference Call to Discuss Acquisition of Delsym(r) 12-Hour Cough Suppressant Liquids From UCB May 25, 2006

  2. Slide 2: Safe Harbor

    Slide 2: Safe Harbor

    Safe Harbor This presentation contains certain "forward-looking" statements. These statements are based on the current estimates and assumptions of the management of Adams Respiratory Therapeutics, Inc. (or "Adams") as of the date of this presentation and are naturally subject to uncertainty and cha

  3. Slide 3: Strategic Rationale for Delsym Acquisition

    Slide 3: Strategic Rationale for Delsym Acquisition

    Delsym(r) is the only FDA-approved over-the-counter (OTC) 12-hour liquid cough suppressant Delsym(r) is the subject of an NDA Delsym(r) is the No. 2 brand in the $300 MM OTC cough syrup category* Delsym(r) has 13% dollar market share* *Source: Information Resources Inc. (IRI) data for the 52 weeks e

  4. Slide 4: Strategic Rationale for Delsym Acquisition

    Slide 4: Strategic Rationale for Delsym Acquisition

    Strategic Rationale for Delsym(r) Acquisition Increases Adams' critical mass within the respiratory space and provides a strategic foothold in the OTC cough syrup segment Adams gains additional proprietary drug delivery technology Leverages Adams' core competency: synergistic approach to consumer an

  5. Slide 5: Terms of the Delsym Acquisition

    Slide 5: Terms of the Delsym Acquisition

    Terms of the Delsym(r) Acquisition One-time, upfront payment of $122 million Purchase of finished goods inventory Modest royalty for 5 years (based on net factory sales) Standard manufacturing supply agreement with UCB based on a "cost-plus" structure Separate license agreement for the Delsym(r) 12-

  6. Slide 6: Financial Projections for Delsym

    Slide 6: Financial Projections for Delsym

    Financial Projections for Delsym(r) *Source: IRI data for the 52 weeks ended 12/25/05 in the cough syrup category (F/D/Mx). Leverages existing infrastructure with minimal incremental fixed expense in SG&A Future pretax profit margin for Delsym(r) projected to be in line with Adams' base book of busi

  7. Slide 7: Dextromethorphan Polistirex Extended-Release Suspension

    Slide 7: Dextromethorphan Polistirex Extended-Release Suspension

    Delsym(r) Dextromethorphan Polistirex Extended-Release Suspension Only 12-hour OTC cough liquid U.S. launch: December 1982 Unique Pennkinetic Technology 12-hour duration of action Superior taste masking Alcohol free FDA Orange Book formulation patent (2017) 4 SKU's: 2 Adult/2 Children Longest-lastin

  8. Slide 8: Market Performance

    Slide 8: Market Performance

    Delsym(r) Market Performance Significant sales gains over prior year No. 2 brand in the cough syrup category(1) 13% dollar market share(1) Brand awareness: Pharmacist recommendations solid (52%)(2) despite minimal promotion Consumer awareness is low, currently at 3%(3) Loyal user base Substantial op

  9. Slide 9: How Delsym Works

    Slide 9: How Delsym Works

    Delsym(r) Works Works at the source of the cough for 12 hours Raises the threshold of coughing by acting on the cough reflex The longest-lasting liquid cough remedy available without a prescription Has the optimal dose of a single ingredient Contains 30 mg of dextromethorphan (DM) to achieve the max

  10. Slide 10: Media Approach

    Slide 10: Media Approach

    Media Approach Overall Media Objective Generate broad awareness of Delsym(r) among cough sufferers Plan Strong consumer advertising/promotional support $15 - $20 million annual investment planned

  11. Slide 11: Adams Respiratory Therapeutics

    Slide 11: Adams Respiratory Therapeutics

    ADAMS RESPIRATORY THERAPEUTICS™ I\S

Source: SEC EDGAR · 8-K filed May 25, 2006

More decks from Adams Respiratory Therapeutics Inc